Latest Strategic Review News

Rio Tinto delivered a standout 2025 with an 8% rise in copper equivalent production, record iron ore output in the Pilbara, and key milestones like the first shipment from Simandou port. The company met or exceeded its guidance while advancing major projects across its portfolio.

Kingfisher Mining has completed a strategic acquisition of 11 tenements in New South Wales and commenced drilling at the Copper Blow IOCG prospect, while advancing rare earth element exploration in Western Australia.

Eagle Mountain Mining has launched a Placement Options Offer for 61.3 million options attaching to recent placement shares, potentially raising $1.23 million upon exercise. The offer supports ongoing exploration and strategic initiatives in Arizona copper projects.

Aquirian Limited reports a robust first half of FY26 with revenue up 27.4% and EBITDA more than doubling, driven by strategic facility upgrades and promising joint ventures.

Panther Metals has completed a $315k shortfall placement, bolstering its funding as it plans deeper drilling at Burtville East and initiates a strategic review of its Coglia project in response to soaring cobalt prices.

Adisyn Ltd has completed a strategic review, deciding to boost investment in its graphene-based semiconductor arm while exploring options to unlock value from its managed IT services business.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

360 Capital Group has announced it will not pay a dividend for the first half of fiscal 2026, signaling a cautious approach amid an ongoing strategic review.

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

TT Investments, led by Executive Chairman Tony Pitt, has announced an unconditional all-cash on-market takeover offer for 360 Capital Group at $0.31 per security, representing a 24% premium to recent trading prices. The offer aims to consolidate ownership and may lead to delisting from the ASX.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

GrainCorp announces the sale of its Canadian joint venture GrainsConnect to Parrish & Heimbecker for C$150 million, alongside a trading update revealing lower expected grain receivals in Australia’s 2025-26 winter harvest.